OneMedPlace today announced the final program for its "China
Forum III" that will be held at the Sir
Francis Drake Hotel, San Francisco, from 1-4 pm on January 7, 2013.
This session has become an annual gathering of leading U.S., European,
and Chinese investors and executives who are active in the rapidly
developing healthcare marketplace in China.
"We are very pleased to once again assemble some of the most influential
and prominent investors and executives to discuss how Western
technologies can be applied to the rapidly growing Chinese healthcare
market," said Brett Johnson, CEO of OneMedPlace,
organizer of the China Forum. "I would like to thank my co-chair Tony
Zhang, immediate past Chairman of BayHelix, an organization of
Chinese life science business leaders, who has helped assemble our
"The China Forum has become a focal point for people doing business
in China or wanting to participate in the most vibrant healthcare market
during the JP Morgan conference week. It has been a very effective way
to connect with the industry leaders directly," said Mr. Zhang.
The event will open with remarks from Bin Li, Managing
Director and Senior Research Analyst for China Healthcare, Morgan
Stanley Research. Dr. Li will offer an overview of the Chinese
healthcare secto and provide insight about the major challenges and
opportunities for investors and growth companies looking to capitalize
on China's growing healthcare sector.
Three separate panels reviewing and discussing actual case studies of
transactions involving Western technology and Chinese investors and
management will follow. "We will get perspectives of those engaged in
these deals about what works and what doesn't. The program was created
to give insight to Western companies that are serious about China and
the huge opportunity that exists there," said Johnson.
The session will also include remarks from Ms. Yuwen Liu, the
CEO of BioBay in Suzhou Industrial Park, who will provide her
perspectives about opportunities for Western companies in China.
The Program will focus on specific case studies of joint ventures in
China, successful and otherwise. Assisting in the programming are Philip
Groves, CEO of DAC Management, an alternative management fund active
in China; Landon Lack, CEO of China MedConnect; and David
Chen, Managing Director of BFC Group. Each of these gentlemen has
participated in numerous transactions involved in medical technology
Case situations will also be provided by other conference
panelists who include: Dr. Jimmy Zhang, Managing
Director, MSD Early Investments-Greater China at Merck & Co. and
Chairman of BayHelix; Dr. Jay Dong, General Manager, Asia Pacific
Region, Cell Signaling Technology (CST), Inc., Vice Chairman of
BayHelix; Dr. May Wang, SVP, Business Development, Hutchsion
MediPharma; Dr. Mike Liu, Head, Business Development,
Jiangsu Hengrui Medicine; Dr. Alan Paau, Vice Provost and
Executive Director, Cornell Center for Technology Enterprise &
Commercialization, Cornell University; Dr. Jie D'Elia, Corporate
Vice President of Business Development and Corporate Communications,
President of Simcere of America; Dr. James Tong, CFO, Chief
Business & Development Officer and Director, Tianyin Pharmaceuticals; Mark
Xu, General Manager, Trout Group at Shanghai. This program is
designed to provide guidance for the emerging growth companies in
healthcare and life science companies that attend the OneMedForum and
are part of the OneMedPlace Global Database.
For more information visit the conference website. www.onemedforum.com
[ Back To NFVZone's Homepage ]